3[4]Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer prebiously treated with chemotherapy.J Clin Oncol,2004,22(9):1589-1597.
4[2]Calvert H.An overview of folate metabolism:Features relevant to the action and toxicities of antifolate anticancer agents.Semin Oncol,1999,26(2 Suppl 6):3.
5Vogelzang NJ, Rusthoven JJ, Symanowski J. Phase Ⅲ study ofpemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003, 21 (14):2636-2644.
6Tomek S, Emri S, Krejcy K, et al. Chemotherapy for malignant pleural mesothelioma: past results and recent:development[J]. Br J Cancer, 2003, 88(2): 167-174.
7O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase Ⅱ study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer[J]. Clin Breast Cancer, 2005, 6(2):143-149.
8Miles DW, Smith IE, Coleman RE, et al. Phase Ⅱ study of pemetrexed in patients pretreated with locally recurrentmetastatic breast cancer[J]. Eur J Cancer, 2001, 37(11):1366-1371.
9Goedhals L, van Wijk AL. MTA (LY231514) in advanced advanced carcinoma of the cervix [J]. Ann Oncol,1998, 9:339a.
10Pivot X, Raymond E, Laguerre B. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck [J]. Br J Cancer,2001, 85(5):649-655.
